Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Conditions
Brief summary
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for cancer-related pain. While opioids are commonly used in palliative care settings to manage cancer-related pain, their significant side effects, complicated administration requirements, and concerns about addiction can make it challenging for patients to use opioids safely and effectively. Some patients may even avoid opioids altogether because of these concerns, even when opioids are clinically indicated, leading to poor symptom control. To address these challenges, a telehealth education session was developed as a clinical initiative by a palliative care pharmacist, addressing safe and effective opioid management. Educational priorities and session content were informed by a survey of interdisciplinary palliative care clinicians that identified barriers and facilitators to opioid education and key patient educational needs. Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. This study will assess the feasibility and acceptability of delivering the intervention, as well as its preliminary effects on opioid knowledge and self-efficacy. If feasible and acceptable, this pharmacist-led telehealth education model could represent a scalable strategy to improve opioid management for patients with cancer-related pain.
Detailed description
OUTLINE: Patients scheduled to attend a pharmacist-led group telehealth opioid education session who enroll in the study will complete a survey before the session and another survey afterward. After attending the pharmacist education session, patients will receive a patient education handout summarizing the educational content. After attending the pharmacist education session, participants will complete the final survey within 1 month, concluding their participation.
Interventions
OTHERSurvey Administration
Ancillary studies - pre- and post-session surveys to assess opioid knowledge and self-efficacy, and post-session to assess session acceptability
OTHERElectronic Health Record Review
Ancillary studies
Sponsors
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years, consistent with the population of patients treated at Fred Hutch Cancer Center * A cancer diagnosis * Established care in the Fred Hutch Palliative Care Clinic (≥ 1 visit with a Fred Hutch palliative care physician or advanced practice provider within the past 12 months) * Prescribed opioids, defined as either ≥ 1 opioid prescription within the past 6 months documented in the Washington Prescription Drug Monitoring Program (PDMP), or a new opioid prescription initiated by the referring palliative care provider at the time of referral * Ability to understand and willingness to agree to an electronic consent document * Enrolled in MyChart and ability to participate in a telehealth video visit
Exclusion criteria
* Patients who prefer a language other than English for healthcare, as the session will be conducted live and cannot currently be offered in other languages
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of referred patients who attend pharmacist education session (Feasibility) | Up to 6 months | Feasibility of the pharmacist education session will be interpreted as an overall session attendance-to-referral rate ≥ 50%. |
| Participant score on the "general acceptability" item of the Theoretical Framework of Acceptability questionnaire | Up to 1 month post-session | Assessed on post-session surveys, delivered within 7 days after session attendance, with up to one month of follow-up to encourage survey completion. Acceptability of the pharmacist education session will be interpreted as \> 70% respondents rating the sessions as ≥ 4/5 (i.e. "acceptable" or "completely acceptable") on the "general acceptability" item of the Theoretical Framework of Acceptability scale (5 point Likert scale), assessed on the post-session survey. |
Countries
United States
Contacts
CONTACTSheri Ballard
PRINCIPAL_INVESTIGATORNicole Dussault, MD, MS
Fred Hutch/University of Washington Cancer Consortium
Outcome results
None listed